Recent Company News

• 01:17 AM ET May 02, 2025
  

  Sandoz Group upgraded to outperform from sector perform at RBC Capital Markets (CHF 35.78, 0.00)

• 04:53 PM ET Apr 29, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:04 AM ET Apr 29, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 01:04 AM ET Apr 30, 2025
  

  Sandoz Group reports Q1 revenue $2.48B vs FactSet $2.59B [3 est, $2.54-2.65B]; confirms FY guidance (CHF 36.68, 0.00)

• 01:00 AM ET Apr 30, 2025
  

  Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

• 11:00 AM ET Apr 29, 2025
  

  Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

• 06:24 AM ET Apr 29, 2025
  

  Shanghai Henlius Biotech grants Sandoz an exclusive license to commercialize HLX13 in certain territories (HK$38.35, 0.00)

• 10:39 PM ET Apr 25, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap